Nona Biosciences Announces Strategic Collaboration Agreement with PharmaEssentia Innovation Research Center

CAMBRIDGE,Mass.,May 12,2023 --Nona Biosciences,a wholly-owned subsidiary of HBM Holdings Limited,committed to cutting-edge technology innovation and provider of integrated solutions from "Idea to IND" (I to I™),announced today it has entered into a strategic collaboration agreement with Massachusetts-based PharmaEssentia Innovation Research Center (PIRC) on Nona's proprietary Harbour Mice® fully human antibody transgenic mice platform.

"We are pleased to enter this strategic collaboration with PharmaEssentia," Jingsong Wang,M.D.,PhD,Chairman of Nona Biosciences,said," PharmaEssentia's therapeutic solutions reflect its motivation for reshaping the treatment path for progressive cancers,and we believe that by leveraging Nona's antibody discovery ability,we can accelerate the R&D process of novel therapies."

"We are delighted to partner with Nona Biosciences as we continue to expand our research capabilities and technical expertise at our newly established PIRC," said Lih-Ling Lin PhD,Chief Scientific Officer of PharmaEssentia "We look forward to growing our footprint in the Boston area as we assemble our team of scientists and complete the build-out of our new lab space this year."

About Nona Biosciences

Nona Biosciences (a wholly-owned subsidiary of HBM Holdings,HKEX: 02142) is a global biotechnology company committed to cutting edge technology innovation,and providing a total solution from "Idea to IND" (I to I™),ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation,animal immunization,single B cell screening,to antibody lead generation and engineering,developability assessment and pharmacological evaluation,leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team.

Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format,and heavy chain only (HCAb) formats. Integrating Harbour Mice® and a single B cell cloning platform,Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information,please visit:www.nonabio.com